Clinical trials: psoriasis
Psoriasis
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 139 in Healthy Subjects and Subjects With Moderate to Severe Psoriasis
The purpose of this study is to assess the safety and tolerability of AMG 139 following single subcutaneous (SC) or intravenous (IV) dose administration in healthy subjects and subjects with moderate to severe psoriasis (PsO).
- Trial name
- NCT01094093
- Testing
- AMG 139
- Where
- 4 sites in Australia, New Zealand
- Volunteers
- 73 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Plaque Psoriasis
A Safety Study of 188-0551 Spray Versus Reference Listed Drug (RLD) in Adult Subjects With Plaque Psoriasis
Adrenal suppression effects of corticosteroids are among the most important safety concerns for this group of products. This study is to determine and compare the adrenal suppression potential and the pharmacokinetic (PK)…
- Trial name
- NCT04080206
- Testing
- 188-0551 Spray, RLD
- Where
- 8 sites in United States, Georgia and 1 more
- Volunteers
- 55 people
- Sponsor
- Therapeutics, Inc.
Moderate-to-Severe Plaque Psoriasis
Efficacy 、Safety and PK of SHR-1314 in Patients With Moderate-to-Severe Plaque Psoriasis
The purpose of this study is to assess efficacy, safety, pharmacokinetics and immunogenicity of subcutaneous SHR-1314 in Patients with Moderate-to-Severe Plaque Psoriasis
- Trial name
- NCT04839016
- Testing
- SHR-1314
- Volunteers
- 660 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Plaque Psoriasis
AGN-242428 in the Treatment of Plaque Psoriasis
The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of AGN-242428 in adult participants with moderate to severe plaque-type psoriasis.
- Trial name
- NCT03339999
- Testing
- AGN-242428
- Where
- 15 sites in United States
- Volunteers
- 24 people
- Sponsor
- Vitae Pharmaceuticals, Inc.
Chronic Pruritus Due to Plaque Psoriasis
An Exploratory Study to Assess the Efficacy of the Avène Hydrotherapy
To assess the benefit of the Avène hydrotherapy in subjects with pruritic plaque psoriasis
- Trial name
- PAP (NCT03023254)
- Testing
- Hydrotherapy
- Where
- 29 sites in France, Spain
- Volunteers
- 44 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Psoriasis
A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)
The reason for this study is to see how effective and safe mirikizumab is compared to secukinumab and placebo for moderate to severe plaque psoriasis.
- Trial name
- NCT03535194
- Testing
- Mirikizumab, Secukinumab
- Where
- 178 sites in United States, Argentina and 14 more
- Volunteers
- 1,484 people
- Sponsor
- Eli Lilly and Company
Psoriasis
A First in Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Intravenous (IV) Dose of GSK2831781 in Healthy Volunteers and Patients With Plaque Psoriasis
This study is a phase I, randomised, double blind (sponsor unblinded), placebo-controlled, single ascending dose study GSK2831781 administered by IV.
- Trial name
- NCT02195349
- Testing
- GSK2831781
- Where
- 3 sites in Germany, United Kingdom
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Psoriasis
International Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of BCD-085 in Various Doses in Patients With Moderate to Severe Plaque Psoriasis
BCD-085-2 is a next step in clinical investigation of BCD-085. BCD-085 is a monoclonal antibody to interleukin 17. During BCD-085-2 trial patients with moderate to severe plaque psoriasis, in whom poor response to previous…
- Trial name
- NCT02762994
- Testing
- BCD-085
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biocad
Psoriasis Vulgaris
A Maximal Use Trial Evaluating the Pharmacokinetic Profile of MC2-01 Cream in Adolescent Subjects
This is a phase 2, open-label, single-group, multicentre trial in which the investigational product, MC2-01 cream, is investigated in adolescent subjects (age 12 to 16 years, 11 months) with clinically diagnosed extensive…
- Trial name
- NCT03819218
- Testing
- MC2-01 cream
- Where
- 2 sites in Czechia, Germany
- Volunteers
- 7 people
- Sponsor
- MC2 Therapeutics
Psoriasis Vulgaris
Body PSOriasis: Long-term Relapse CONTROL
This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow…
- Trial name
- PSO-CONTROL (NCT03402828)
- Testing
- Any topical drug treatment
- Where
- Russia
- Volunteers
- 764 people
- Sponsor
- LEO Pharma
Psoriasis
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
The primary objective of this study was to evaluate the safety and efficacy of risankizumab (150 mg/mL) administered by prefilled syringe (PFS) for the treatment of adult participants with moderate to severe plaque psoriasis.
- Trial name
- NCT03875482
- Testing
- Risankizumab
- Where
- 43 sites in United States, Puerto Rico
- Volunteers
- 157 people
- Sponsor
- AbbVie
Healthy Volunteers, Psoriasis
A Multiple Dose Study of BAY1834845 in Healthy Male Subjects and in Patients With Psoriasis
To assess safety and tolerability of multiple oral doses of BAY1834845 in healthy male subjects (Part 1) and in patients with psoriasis (Part 2).
- Trial name
- NCT03493269
- Testing
- BAY1834845, Midazolam
- Where
- 2 sites in Germany
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Bayer
Chronic Plaque Psoriasis
A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis
This is an open-label, multicenter study to assess the systemic exposure to calcitriol in the adolescent population. Calcitriol 3µg/g ointment (2 mg/cm² per application) is to be applied twice daily to involved skin (10 - 35% BSA…
- Trial name
- NCT00419666
- Testing
- Calcitriol 3mcg/g
- Where
- 7 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Galderma R&D
Scalp Psoriasis
Subject Preference for Scalp Psoriasis Treatment
The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress.
- Trial name
- NCT00438399
- Testing
- C. propionate - Corticosteroid 1, C. propionate- Corticosteroid 2, C. propionate -Corticosteroid 3
- Where
- Italy
- Volunteers
- 219 people
- Sponsor
- Galderma R&D
Plaque-type Psoriasis
Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of CD 2027 Spray in Adults With Plaque-type Psoriasis
This is a multicenter, open-label study to assess systemic plasma levels of calcitriol, calcium homeostasis and safety in adults with plaque-type psoriasis under conditions of maximized use of CD 2027 3µg/g oily spray twice daily…
- Trial name
- NCT00763503
- Testing
- CD 2027
- Where
- 3 sites in United States
- Volunteers
- 26 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
PK and PD Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The purpose of this study is to determine if the calcitriol absorption in pediatric subjects is comparable to that in adults and adolescents, with no significant impact on calcium/phosphorus metabolism.
- Trial name
- NCT01766440
- Testing
- Calcitriol 3 mcg/g ointment
- Where
- 8 sites in United States
- Volunteers
- 18 people
- Sponsor
- Galderma R&D
Psoriasis Vulgaris
Long Term Safety and Efficacy Study of Calcitriol 3 mcg/g Ointment in Pediatric Subjects With Plaque Psoriasis
The objective of this study is to evaluate the safety and efficacy of up to 26 weeks of treatment with calcitriol 3 mcg/g ointment when used twice daily, without occlusion, to treat pediatric subjects (2 to 16 years and 11 months…
- Trial name
- NCT02125279
- Testing
- Calcitriol
- Where
- 16 sites in United States, Belgium and 3 more
- Volunteers
- 54 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
Plaque Psoriasis Study in Pediatric Subjects
The purpose of this study is to compare the safety, efficacy and calcium metabolism of up to 8 weeks of treatment with calcitriol 3 mcg/g ointment versus its vehicle, when used twice daily, without occlusion, to treat children…
- Trial name
- NCT02186665
- Testing
- calcitriol ointment
- Where
- 34 sites in United States, Belgium and 5 more
- Volunteers
- 19 people
- Sponsor
- Galderma R&D
Psoriasis
The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis
The purpose of this research study is to compare the efficacy and safety of SCT630 and adalimumab (HUMIRA®) in adults with plaque psoriasis.
- Trial name
- NCT03927352
- Testing
- SCT630, Adalimumab
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Sinocelltech Ltd.
Psoriasis
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
The purpose of this study is to assess the safety and efficacy of risankizumab compared to placebo in subjects with moderate to severe chronic plaque psoriasis in the Russian Federation.
- Trial name
- IMMPRESS (NCT03518047)
- Testing
- risankizumab
- Where
- 6 sites in Russia
- Volunteers
- 50 people
- Sponsor
- AbbVie